Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Short term Debt: 2014-2025

Historic Short term Debt for Coherus Oncology (CHRS) over the last 4 years, with Mar 2025 value amounting to $26.2 million.

  • Coherus Oncology's Short term Debt was N/A to $26.2 million in Q1 2025 from the same period last year, while for Mar 2025 it was $26.2 million, marking a year-over-year change of. This contributed to the annual value of $13.6 million for FY2024, which is 312.73% up from last year.
  • Latest data reveals that Coherus Oncology reported Short term Debt of $26.2 million as of Q1 2025, which was up 92.57% from $13.6 million recorded in Q4 2024.
  • Over the past 5 years, Coherus Oncology's Short term Debt peaked at $26.2 million during Q1 2025, and registered a low of $90,000 during Q2 2023.
  • For the 3-year period, Coherus Oncology's Short term Debt averaged around $8.2 million, with its median value being $6.6 million (2023).
  • Data for Coherus Oncology's Short term Debt shows a peak YoY soared of 10,124.44% (in 2024) over the last 5 years.
  • Quarterly analysis of 4 years shows Coherus Oncology's Short term Debt stood at $17.3 million in 2021, then reached $3.3 million in 2023, then skyrocketed by 312.73% to $13.6 million in 2024, then reached $26.2 million in 2025.
  • Its last three reported values are $26.2 million in Q1 2025, $13.6 million for Q4 2024, and $9.2 million during Q3 2024.